The clinical trial results of Tirzepatide against OSA are about to be released

In today’s society, obesity has become an increasingly serious global problem, and obesity can cause many complications. Among them, obstructive sleep apnea (OSA) is a major health problem closely related to obesity. The weight loss drug product Tirzepatide is about to face a new test: can it provide satisfactory results in phase III clinical trials against OSA?

The purpose of the experiment is to evaluate the efficacy and safety of Tirzepatide in OSA patients and obese patients. The results of the three phase clinical trials mentioned above are expected to be announced from the end of March to early April.

There is a close relationship between obesity and OSA. Previous studies have shown that obesity is one of the main risk factors for OSA, and vice versa. Weight loss surgery has also been shown to have a positive impact on obesity related OSA. A study in Wisconsin, USA found that 41% of adult OSA cases are attributed to overweight or obesity. Morgan Stanley wrote in a report that there are approximately 31 million mild OSA patients, 14 million moderate OSA patients, and 8 million severe OSA patients in the United States based on the severity of OSA.

Therefore, if Tirzepatide can significantly improve OSA beyond its weight loss effect, it will undoubtedly open up new avenues for the treatment of this disease.